# Anthrax AV7909 Boost Evaluation Study

> **NCT05997264** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biomedical Advanced Research and Development Authority** · enrollment: 220 (actual)

## Conditions studied

- Anthrax

## Interventions

- **BIOLOGICAL:** AV7909 Full Dose (0.5 mL)
- **BIOLOGICAL:** AV7909 Half Dose (0.25 mL)
- **BIOLOGICAL:** Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL)
- **BIOLOGICAL:** Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)

## Key facts

- **NCT ID:** NCT05997264
- **Lead sponsor:** Biomedical Advanced Research and Development Authority
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-05
- **Primary completion:** 2025-08-28
- **Final completion:** 2026-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997264, "Anthrax AV7909 Boost Evaluation Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05997264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*